| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 68 | 2024 | 384 | 8.460 |
Why?
|
| Tuberous Sclerosis | 46 | 2025 | 124 | 7.850 |
Why?
|
| Epilepsy | 42 | 2025 | 898 | 5.400 |
Why?
|
| Neurosurgical Procedures | 29 | 2025 | 316 | 5.030 |
Why?
|
| Microglia | 12 | 2025 | 139 | 4.220 |
Why?
|
| Drug Resistant Epilepsy | 19 | 2025 | 225 | 4.000 |
Why?
|
| Neurosurgery | 7 | 2025 | 78 | 3.100 |
Why?
|
| Brain Neoplasms | 25 | 2024 | 1406 | 2.350 |
Why?
|
| Brain | 47 | 2025 | 3225 | 2.270 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 13 | 2025 | 47 | 2.220 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 10 | 2025 | 42 | 2.160 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 8 | 2025 | 21 | 2.160 |
Why?
|
| Interleukin-10 | 5 | 2025 | 191 | 1.970 |
Why?
|
| Magnetic Resonance Imaging | 62 | 2025 | 3867 | 1.820 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2025 | 237 | 1.770 |
Why?
|
| Gray Matter | 7 | 2019 | 44 | 1.760 |
Why?
|
| Antibodies, Monoclonal | 7 | 2025 | 1066 | 1.750 |
Why?
|
| Vagus Nerve Stimulation | 7 | 2025 | 57 | 1.650 |
Why?
|
| Seizures | 20 | 2023 | 892 | 1.530 |
Why?
|
| Positron-Emission Tomography | 8 | 2025 | 312 | 1.520 |
Why?
|
| Epilepsies, Partial | 8 | 2018 | 95 | 1.460 |
Why?
|
| Alzheimer Disease | 11 | 2025 | 883 | 1.460 |
Why?
|
| Glial Fibrillary Acidic Protein | 6 | 2025 | 116 | 1.460 |
Why?
|
| Electroencephalography | 26 | 2024 | 897 | 1.430 |
Why?
|
| Pediatrics | 5 | 2025 | 1221 | 1.420 |
Why?
|
| CD3 Complex | 2 | 2025 | 91 | 1.400 |
Why?
|
| Humans | 250 | 2025 | 134143 | 1.350 |
Why?
|
| Child | 96 | 2025 | 25911 | 1.280 |
Why?
|
| Cerebral Cortex | 16 | 2022 | 482 | 1.190 |
Why?
|
| Neurosurgeons | 2 | 2025 | 15 | 1.170 |
Why?
|
| Male | 157 | 2025 | 66171 | 1.160 |
Why?
|
| Supratentorial Neoplasms | 2 | 2023 | 40 | 1.120 |
Why?
|
| Neurofilament Proteins | 7 | 2025 | 36 | 1.120 |
Why?
|
| Astrocytoma | 11 | 2020 | 112 | 1.110 |
Why?
|
| Child, Preschool | 72 | 2025 | 14895 | 1.110 |
Why?
|
| Th17 Cells | 4 | 2025 | 100 | 1.100 |
Why?
|
| Female | 160 | 2025 | 72002 | 1.090 |
Why?
|
| Stereotaxic Techniques | 5 | 2024 | 68 | 1.090 |
Why?
|
| Laser Therapy | 3 | 2024 | 229 | 1.030 |
Why?
|
| Treatment Outcome | 54 | 2025 | 13098 | 1.020 |
Why?
|
| Muscle Relaxants, Central | 5 | 2016 | 39 | 1.010 |
Why?
|
| Baclofen | 5 | 2016 | 45 | 1.010 |
Why?
|
| Central Nervous System | 8 | 2025 | 285 | 0.990 |
Why?
|
| Hemispherectomy | 5 | 2024 | 26 | 0.990 |
Why?
|
| Hydrocephalus | 9 | 2022 | 276 | 0.980 |
Why?
|
| Cerebellar Diseases | 3 | 2022 | 81 | 0.940 |
Why?
|
| Phagocytosis | 3 | 2025 | 194 | 0.930 |
Why?
|
| Adult | 96 | 2025 | 31943 | 0.930 |
Why?
|
| Electrodes, Implanted | 8 | 2024 | 164 | 0.910 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2016 | 139 | 0.900 |
Why?
|
| Efficiency | 1 | 2025 | 70 | 0.900 |
Why?
|
| Immunosuppressive Agents | 9 | 2020 | 680 | 0.900 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2025 | 556 | 0.900 |
Why?
|
| Encephalitis | 5 | 2022 | 122 | 0.890 |
Why?
|
| Fatigue | 4 | 2020 | 202 | 0.870 |
Why?
|
| Malformations of Cortical Development | 3 | 2022 | 54 | 0.870 |
Why?
|
| Retrospective Studies | 59 | 2025 | 17565 | 0.850 |
Why?
|
| Physician Assistants | 1 | 2025 | 77 | 0.850 |
Why?
|
| Feces | 2 | 2025 | 789 | 0.850 |
Why?
|
| Astrocytes | 5 | 2025 | 273 | 0.830 |
Why?
|
| Mentors | 1 | 2025 | 162 | 0.830 |
Why?
|
| Interferon Type I | 2 | 2025 | 115 | 0.800 |
Why?
|
| Psychosurgery | 1 | 2023 | 27 | 0.800 |
Why?
|
| Muscle Spasticity | 5 | 2016 | 61 | 0.780 |
Why?
|
| Inflammation | 8 | 2024 | 1595 | 0.770 |
Why?
|
| Medulloblastoma | 7 | 2024 | 571 | 0.770 |
Why?
|
| Neuroglia | 2 | 2024 | 215 | 0.760 |
Why?
|
| Administration, Intranasal | 4 | 2025 | 138 | 0.760 |
Why?
|
| Adolescent | 71 | 2025 | 20643 | 0.760 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2022 | 16 | 0.760 |
Why?
|
| Faculty, Medical | 1 | 2025 | 279 | 0.750 |
Why?
|
| Middle Aged | 71 | 2025 | 29395 | 0.750 |
Why?
|
| Cerebellar Neoplasms | 7 | 2024 | 461 | 0.720 |
Why?
|
| Postoperative Complications | 19 | 2024 | 3170 | 0.720 |
Why?
|
| T-Lymphocytes | 13 | 2025 | 1771 | 0.700 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2025 | 301 | 0.690 |
Why?
|
| Hamartoma | 3 | 2018 | 53 | 0.680 |
Why?
|
| Substantia Nigra | 1 | 2020 | 37 | 0.680 |
Why?
|
| Colitis | 3 | 2018 | 173 | 0.670 |
Why?
|
| Education, Medical, Graduate | 1 | 2025 | 563 | 0.660 |
Why?
|
| Quality of Life | 10 | 2025 | 2162 | 0.640 |
Why?
|
| Infant | 45 | 2025 | 13256 | 0.630 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2021 | 211 | 0.620 |
Why?
|
| Follow-Up Studies | 20 | 2025 | 5465 | 0.610 |
Why?
|
| Neurophysiological Monitoring | 2 | 2018 | 37 | 0.600 |
Why?
|
| Interferon-beta | 5 | 2025 | 54 | 0.600 |
Why?
|
| Spinal Cord Neoplasms | 4 | 2023 | 72 | 0.590 |
Why?
|
| Immunologic Factors | 3 | 2016 | 186 | 0.590 |
Why?
|
| Disease Progression | 19 | 2025 | 2265 | 0.590 |
Why?
|
| Biomarkers | 15 | 2025 | 3431 | 0.590 |
Why?
|
| Gene Expression Profiling | 8 | 2021 | 1922 | 0.580 |
Why?
|
| Somatosensory Cortex | 1 | 2018 | 57 | 0.580 |
Why?
|
| Infusion Pumps, Implantable | 4 | 2016 | 42 | 0.570 |
Why?
|
| Neocortex | 2 | 2018 | 76 | 0.570 |
Why?
|
| Cell Death | 1 | 2018 | 251 | 0.560 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2025 | 507 | 0.560 |
Why?
|
| Pneumonia | 1 | 2021 | 343 | 0.560 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2000 | 148 | 0.550 |
Why?
|
| Fingolimod Hydrochloride | 5 | 2017 | 37 | 0.530 |
Why?
|
| Sjogren-Larsson Syndrome | 1 | 2016 | 2 | 0.530 |
Why?
|
| Young Adult | 29 | 2024 | 9960 | 0.530 |
Why?
|
| Meningomyelocele | 3 | 2024 | 255 | 0.520 |
Why?
|
| Cognition Disorders | 5 | 2011 | 579 | 0.520 |
Why?
|
| Muromonab-CD3 | 1 | 2016 | 8 | 0.510 |
Why?
|
| Mice | 27 | 2025 | 19043 | 0.510 |
Why?
|
| Brain Mapping | 7 | 2024 | 405 | 0.500 |
Why?
|
| Mice, Inbred C57BL | 15 | 2025 | 4881 | 0.500 |
Why?
|
| Peyer's Patches | 1 | 2015 | 22 | 0.490 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2015 | 7 | 0.490 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 32 | 0.490 |
Why?
|
| White Matter | 4 | 2019 | 212 | 0.480 |
Why?
|
| Animals | 39 | 2025 | 36518 | 0.470 |
Why?
|
| Hypothalamic Diseases | 1 | 2015 | 38 | 0.470 |
Why?
|
| Craniotomy | 5 | 2016 | 106 | 0.460 |
Why?
|
| Neurons | 6 | 2022 | 2051 | 0.460 |
Why?
|
| Signal Transduction | 11 | 2025 | 4936 | 0.460 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2025 | 823 | 0.450 |
Why?
|
| Spinal Cord | 6 | 2023 | 275 | 0.450 |
Why?
|
| Cytokines | 4 | 2025 | 1397 | 0.450 |
Why?
|
| Apolipoprotein E4 | 2 | 2025 | 48 | 0.450 |
Why?
|
| Adaptation, Psychological | 3 | 2024 | 455 | 0.450 |
Why?
|
| Meningeal Neoplasms | 2 | 2014 | 217 | 0.450 |
Why?
|
| Adjuvants, Immunologic | 3 | 2019 | 391 | 0.450 |
Why?
|
| Radiosurgery | 1 | 2015 | 147 | 0.440 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2014 | 8 | 0.430 |
Why?
|
| Port-Wine Stain | 1 | 2014 | 8 | 0.430 |
Why?
|
| Disease Models, Animal | 10 | 2025 | 4802 | 0.430 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2021 | 216 | 0.420 |
Why?
|
| Glioma | 6 | 2010 | 535 | 0.410 |
Why?
|
| Atrophy | 11 | 2020 | 253 | 0.400 |
Why?
|
| Mutism | 2 | 2024 | 32 | 0.400 |
Why?
|
| MicroRNAs | 5 | 2025 | 949 | 0.400 |
Why?
|
| Flow Cytometry | 7 | 2018 | 824 | 0.380 |
Why?
|
| Reoperation | 9 | 2019 | 851 | 0.380 |
Why?
|
| Cohort Studies | 15 | 2025 | 5219 | 0.380 |
Why?
|
| Trans-Activators | 4 | 2005 | 838 | 0.370 |
Why?
|
| Germinoma | 3 | 2010 | 32 | 0.370 |
Why?
|
| Monitoring, Physiologic | 2 | 2012 | 386 | 0.370 |
Why?
|
| Severity of Illness Index | 12 | 2020 | 3119 | 0.360 |
Why?
|
| Intestinal Mucosa | 2 | 2019 | 816 | 0.360 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2011 | 8 | 0.350 |
Why?
|
| Intracranial Hypotension | 1 | 2011 | 12 | 0.350 |
Why?
|
| Cognitive Dysfunction | 3 | 2025 | 316 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2022 | 3508 | 0.340 |
Why?
|
| Macrophages | 4 | 2019 | 710 | 0.340 |
Why?
|
| Homeostasis | 4 | 2025 | 751 | 0.340 |
Why?
|
| Societies, Medical | 2 | 2025 | 779 | 0.330 |
Why?
|
| Cervical Vertebrae | 3 | 2024 | 121 | 0.330 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2023 | 252 | 0.320 |
Why?
|
| Giant Cell Tumors | 1 | 2009 | 5 | 0.320 |
Why?
|
| Autoimmunity | 2 | 2025 | 182 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 1316 | 0.310 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2000 | 235 | 0.310 |
Why?
|
| Aged | 29 | 2025 | 21789 | 0.310 |
Why?
|
| Frontal Lobe | 2 | 2009 | 122 | 0.310 |
Why?
|
| Drainage | 1 | 2011 | 265 | 0.310 |
Why?
|
| Connectome | 2 | 2022 | 118 | 0.310 |
Why?
|
| Receptors, Immunologic | 3 | 2020 | 128 | 0.300 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2014 | 510 | 0.300 |
Why?
|
| Vagus Nerve | 3 | 2023 | 47 | 0.300 |
Why?
|
| Disability Evaluation | 6 | 2025 | 195 | 0.300 |
Why?
|
| Neurodegenerative Diseases | 2 | 2025 | 285 | 0.290 |
Why?
|
| Receptors, Growth Factor | 3 | 2000 | 37 | 0.290 |
Why?
|
| Longitudinal Studies | 12 | 2020 | 1510 | 0.280 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 2 | 2024 | 12 | 0.280 |
Why?
|
| Meningocele | 2 | 2019 | 18 | 0.280 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2017 | 616 | 0.280 |
Why?
|
| Injections, Spinal | 6 | 2016 | 136 | 0.280 |
Why?
|
| Stem Cell Transplantation | 2 | 2008 | 252 | 0.270 |
Why?
|
| Syringomyelia | 1 | 2007 | 17 | 0.270 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2010 | 97 | 0.270 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2019 | 66 | 0.270 |
Why?
|
| Vancomycin | 3 | 2025 | 236 | 0.270 |
Why?
|
| Mice, Transgenic | 8 | 2025 | 2538 | 0.270 |
Why?
|
| Hippocampus | 4 | 2024 | 864 | 0.270 |
Why?
|
| Ependymoma | 4 | 2023 | 176 | 0.270 |
Why?
|
| Cerebral Ventricle Neoplasms | 3 | 2015 | 16 | 0.270 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 169 | 0.260 |
Why?
|
| Autoantibodies | 4 | 2022 | 466 | 0.260 |
Why?
|
| Pilot Projects | 6 | 2021 | 1493 | 0.260 |
Why?
|
| Gene Targeting | 2 | 2017 | 185 | 0.260 |
Why?
|
| Cyclophosphamide | 3 | 2005 | 426 | 0.260 |
Why?
|
| Hemodynamics | 1 | 2011 | 871 | 0.260 |
Why?
|
| Endoscopy | 5 | 2015 | 287 | 0.250 |
Why?
|
| Cells, Cultured | 6 | 2021 | 3180 | 0.250 |
Why?
|
| Antigens, CD | 3 | 2019 | 448 | 0.250 |
Why?
|
| Interferon-gamma | 3 | 2017 | 536 | 0.250 |
Why?
|
| Skull | 3 | 2019 | 145 | 0.250 |
Why?
|
| Vein of Galen Malformations | 1 | 2025 | 15 | 0.240 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2025 | 15 | 0.240 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2025 | 99 | 0.240 |
Why?
|
| Receptors, CXCR3 | 1 | 2025 | 23 | 0.230 |
Why?
|
| Xenon | 1 | 2025 | 13 | 0.230 |
Why?
|
| Prospective Studies | 10 | 2025 | 6610 | 0.230 |
Why?
|
| Odontoid Process | 1 | 2024 | 10 | 0.230 |
Why?
|
| Oncogene Proteins | 2 | 2002 | 157 | 0.230 |
Why?
|
| Brain Stem | 3 | 1997 | 119 | 0.230 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2024 | 18 | 0.230 |
Why?
|
| Neuroendoscopy | 2 | 2015 | 31 | 0.230 |
Why?
|
| Chordoma | 1 | 2024 | 23 | 0.230 |
Why?
|
| Efficiency, Organizational | 1 | 2025 | 62 | 0.230 |
Why?
|
| Auditory Cortex | 1 | 2024 | 28 | 0.230 |
Why?
|
| Ataxia | 3 | 2018 | 177 | 0.220 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 1853 | 0.220 |
Why?
|
| Proteomics | 3 | 2024 | 603 | 0.220 |
Why?
|
| Education, Distance | 1 | 2025 | 67 | 0.220 |
Why?
|
| Central Nervous System Diseases | 3 | 2014 | 109 | 0.220 |
Why?
|
| Streptococcus anginosus | 1 | 2024 | 10 | 0.220 |
Why?
|
| Speech Perception | 1 | 2024 | 57 | 0.220 |
Why?
|
| Recurrence | 7 | 2023 | 1470 | 0.220 |
Why?
|
| Speech | 1 | 2024 | 78 | 0.220 |
Why?
|
| Lennox Gastaut Syndrome | 1 | 2023 | 8 | 0.210 |
Why?
|
| Amyloidosis | 1 | 2025 | 73 | 0.210 |
Why?
|
| Immunity | 2 | 2022 | 184 | 0.210 |
Why?
|
| Tauopathies | 1 | 2025 | 78 | 0.210 |
Why?
|
| Mastoiditis | 1 | 2024 | 33 | 0.210 |
Why?
|
| Hysterotomy | 1 | 2024 | 127 | 0.210 |
Why?
|
| Indoles | 1 | 2025 | 204 | 0.210 |
Why?
|
| Laparotomy | 1 | 2024 | 143 | 0.210 |
Why?
|
| Acetanilides | 2 | 2020 | 8 | 0.210 |
Why?
|
| Brain Abscess | 1 | 2024 | 54 | 0.210 |
Why?
|
| Otitis Media | 1 | 2024 | 89 | 0.210 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2020 | 547 | 0.210 |
Why?
|
| Gene Expression Regulation | 8 | 2024 | 2669 | 0.210 |
Why?
|
| Craniosynostoses | 3 | 2002 | 134 | 0.200 |
Why?
|
| Cerebrovascular Trauma | 1 | 2023 | 4 | 0.200 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2025 | 456 | 0.200 |
Why?
|
| Major Histocompatibility Complex | 1 | 2022 | 53 | 0.200 |
Why?
|
| Spinal Cord Injuries | 3 | 2020 | 284 | 0.200 |
Why?
|
| Sinusitis | 1 | 2024 | 114 | 0.200 |
Why?
|
| Intracranial Pressure | 2 | 2015 | 212 | 0.200 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2024 | 194 | 0.200 |
Why?
|
| Interferon beta-1a | 3 | 2018 | 20 | 0.200 |
Why?
|
| Multiple System Atrophy | 1 | 2022 | 18 | 0.200 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2025 | 336 | 0.200 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 405 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2024 | 235 | 0.190 |
Why?
|
| Clone Cells | 3 | 2021 | 180 | 0.190 |
Why?
|
| Multiple Trauma | 1 | 2023 | 63 | 0.190 |
Why?
|
| Bile Acids and Salts | 1 | 2025 | 259 | 0.190 |
Why?
|
| Burnout, Professional | 1 | 2024 | 130 | 0.190 |
Why?
|
| Interferon beta-1b | 2 | 2019 | 3 | 0.190 |
Why?
|
| Mice, Knockout | 4 | 2024 | 4012 | 0.190 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2022 | 7 | 0.190 |
Why?
|
| Putamen | 1 | 2022 | 21 | 0.190 |
Why?
|
| Reproducibility of Results | 6 | 2025 | 3056 | 0.190 |
Why?
|
| Gliosis | 2 | 2015 | 33 | 0.190 |
Why?
|
| Mesencephalon | 1 | 2022 | 39 | 0.190 |
Why?
|
| Genotype | 4 | 2021 | 2822 | 0.190 |
Why?
|
| RNA | 2 | 2018 | 607 | 0.190 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2022 | 40 | 0.190 |
Why?
|
| Neutrophils | 1 | 2024 | 401 | 0.180 |
Why?
|
| Glatiramer Acetate | 2 | 2019 | 13 | 0.180 |
Why?
|
| Fellowships and Scholarships | 1 | 2025 | 316 | 0.180 |
Why?
|
| Spasms, Infantile | 1 | 2023 | 175 | 0.180 |
Why?
|
| Phenotype | 6 | 2020 | 4605 | 0.180 |
Why?
|
| T Cell Transcription Factor 1 | 2 | 2024 | 7 | 0.180 |
Why?
|
| Immunohistochemistry | 6 | 2018 | 1764 | 0.180 |
Why?
|
| Streptococcal Infections | 1 | 2024 | 248 | 0.180 |
Why?
|
| Home Infusion Therapy | 1 | 2001 | 6 | 0.180 |
Why?
|
| Alemtuzumab | 2 | 2018 | 88 | 0.180 |
Why?
|
| Adrenoleukodystrophy | 1 | 2001 | 8 | 0.180 |
Why?
|
| Receptors, Mitogen | 1 | 2000 | 4 | 0.180 |
Why?
|
| B-Lymphocytes | 2 | 2022 | 542 | 0.170 |
Why?
|
| Neuropsychological Tests | 6 | 2024 | 991 | 0.170 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 318 | 0.170 |
Why?
|
| Language Development Disorders | 1 | 2022 | 179 | 0.170 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2023 | 225 | 0.170 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 4 | 0.170 |
Why?
|
| Toluidines | 1 | 2020 | 4 | 0.170 |
Why?
|
| Crotonates | 1 | 2020 | 7 | 0.170 |
Why?
|
| Perioperative Period | 1 | 2020 | 54 | 0.170 |
Why?
|
| Phosphatidylcholines | 1 | 2020 | 39 | 0.170 |
Why?
|
| Microsurgery | 3 | 2013 | 65 | 0.170 |
Why?
|
| Fetoscopy | 1 | 2024 | 449 | 0.170 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 232 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 317 | 0.160 |
Why?
|
| Glioblastoma | 3 | 2019 | 372 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 2170 | 0.160 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 1999 | 6 | 0.160 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2011 | 84 | 0.160 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 240 | 0.160 |
Why?
|
| Microscopy, Confocal | 2 | 2018 | 367 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 150 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 225 | 0.160 |
Why?
|
| Demyelinating Diseases | 3 | 2014 | 71 | 0.160 |
Why?
|
| Infratentorial Neoplasms | 1 | 2020 | 48 | 0.160 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 9 | 0.160 |
Why?
|
| In Vitro Techniques | 4 | 2015 | 986 | 0.160 |
Why?
|
| Brain Edema | 1 | 2020 | 71 | 0.160 |
Why?
|
| Age of Onset | 4 | 2021 | 638 | 0.160 |
Why?
|
| Dystonia | 1 | 2001 | 173 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2020 | 442 | 0.160 |
Why?
|
| Outpatients | 1 | 2021 | 276 | 0.160 |
Why?
|
| Gadolinium | 5 | 2023 | 117 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2021 | 450 | 0.150 |
Why?
|
| Apyrase | 1 | 2019 | 21 | 0.150 |
Why?
|
| Kynurenine | 1 | 2019 | 26 | 0.150 |
Why?
|
| Image Enhancement | 3 | 2020 | 173 | 0.150 |
Why?
|
| Cerebrospinal Fluid Shunts | 3 | 2001 | 95 | 0.150 |
Why?
|
| Databases, Factual | 4 | 2017 | 1258 | 0.150 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2019 | 83 | 0.150 |
Why?
|
| United States | 7 | 2025 | 11777 | 0.150 |
Why?
|
| Proteolysis | 1 | 2020 | 198 | 0.150 |
Why?
|
| Skull Neoplasms | 1 | 1999 | 16 | 0.150 |
Why?
|
| Caloric Restriction | 1 | 2019 | 96 | 0.150 |
Why?
|
| Rotarod Performance Test | 1 | 2018 | 15 | 0.150 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2018 | 9 | 0.150 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2018 | 12 | 0.150 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 100 | 0.150 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2018 | 2 | 0.150 |
Why?
|
| Drug Resistance | 3 | 2011 | 264 | 0.150 |
Why?
|
| Dura Mater | 1 | 1999 | 26 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 596 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2018 | 11 | 0.150 |
Why?
|
| Optic Nerve | 1 | 2020 | 119 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2023 | 307 | 0.150 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 298 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 2 | 2019 | 701 | 0.150 |
Why?
|
| Steroids | 1 | 2020 | 211 | 0.150 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2020 | 35 | 0.150 |
Why?
|
| Minocycline | 1 | 2018 | 42 | 0.150 |
Why?
|
| Skull Fractures | 1 | 1999 | 43 | 0.150 |
Why?
|
| Transcriptome | 4 | 2019 | 1135 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 471 | 0.150 |
Why?
|
| Monocytes | 3 | 2017 | 357 | 0.150 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2018 | 38 | 0.150 |
Why?
|
| PPAR gamma | 1 | 2018 | 89 | 0.140 |
Why?
|
| Plaque, Amyloid | 3 | 2025 | 69 | 0.140 |
Why?
|
| Mitoxantrone | 1 | 2018 | 27 | 0.140 |
Why?
|
| Temporal Lobe | 3 | 2016 | 118 | 0.140 |
Why?
|
| Proteome | 1 | 2020 | 282 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2021 | 503 | 0.140 |
Why?
|
| Electric Stimulation Therapy | 2 | 2012 | 86 | 0.140 |
Why?
|
| Cytarabine | 1 | 2018 | 102 | 0.140 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 171 | 0.140 |
Why?
|
| Medical Oncology | 1 | 1999 | 247 | 0.140 |
Why?
|
| Face | 1 | 2019 | 190 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 1332 | 0.140 |
Why?
|
| Vaccines | 1 | 2022 | 380 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 358 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 546 | 0.130 |
Why?
|
| Mass Spectrometry | 2 | 2020 | 367 | 0.130 |
Why?
|
| Comorbidity | 2 | 2020 | 1627 | 0.130 |
Why?
|
| Th1 Cells | 1 | 2017 | 159 | 0.130 |
Why?
|
| Nerve Net | 1 | 2020 | 259 | 0.130 |
Why?
|
| Spinal Osteophytosis | 2 | 1993 | 4 | 0.130 |
Why?
|
| Apolipoproteins E | 1 | 2017 | 205 | 0.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 239 | 0.130 |
Why?
|
| Time Factors | 9 | 2020 | 6592 | 0.130 |
Why?
|
| Virology | 1 | 2016 | 36 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 2 | 2016 | 390 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1357 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2018 | 457 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 868 | 0.130 |
Why?
|
| Anticonvulsants | 3 | 2011 | 396 | 0.130 |
Why?
|
| Allergy and Immunology | 1 | 2016 | 29 | 0.130 |
Why?
|
| Therapy, Computer-Assisted | 1 | 1996 | 24 | 0.130 |
Why?
|
| Cell Communication | 2 | 2016 | 192 | 0.130 |
Why?
|
| CD56 Antigen | 1 | 2016 | 29 | 0.130 |
Why?
|
| Embryo, Mammalian | 2 | 2013 | 467 | 0.130 |
Why?
|
| Aging | 2 | 2021 | 1308 | 0.130 |
Why?
|
| Nervous System Neoplasms | 1 | 2016 | 11 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2018 | 309 | 0.130 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2015 | 3 | 0.120 |
Why?
|
| Animals, Congenic | 1 | 2015 | 7 | 0.120 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2015 | 5 | 0.120 |
Why?
|
| Third Ventricle | 3 | 2015 | 33 | 0.120 |
Why?
|
| Integrins | 1 | 1996 | 103 | 0.120 |
Why?
|
| Mutation | 4 | 2018 | 6341 | 0.120 |
Why?
|
| Ventriculostomy | 3 | 2015 | 44 | 0.120 |
Why?
|
| Hydrocephalus, Normal Pressure | 1 | 1995 | 5 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2015 | 914 | 0.120 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 192 | 0.120 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2016 | 87 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2002 | 2734 | 0.120 |
Why?
|
| Cerebellum | 3 | 2012 | 467 | 0.120 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 133 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 4 | 2025 | 488 | 0.120 |
Why?
|
| Parkinson Disease | 1 | 2022 | 740 | 0.120 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2015 | 41 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 432 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 424 | 0.120 |
Why?
|
| Amyloid beta-Peptides | 3 | 2025 | 246 | 0.120 |
Why?
|
| Artifacts | 1 | 2016 | 114 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 1626 | 0.120 |
Why?
|
| Environment | 1 | 2015 | 156 | 0.110 |
Why?
|
| Galactosyltransferases | 1 | 2014 | 7 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 542 | 0.110 |
Why?
|
| Prognosis | 6 | 2025 | 5084 | 0.110 |
Why?
|
| Glycolipids | 1 | 2014 | 35 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2021 | 1148 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2025 | 1255 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 385 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 396 | 0.110 |
Why?
|
| Craniopharyngioma | 1 | 1994 | 35 | 0.110 |
Why?
|
| Neurology | 1 | 2016 | 120 | 0.110 |
Why?
|
| Propylene Glycols | 1 | 2014 | 19 | 0.110 |
Why?
|
| Sphingosine | 1 | 2014 | 17 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 3 | 2025 | 2587 | 0.110 |
Why?
|
| JC Virus | 1 | 2014 | 29 | 0.110 |
Why?
|
| Hedgehog Proteins | 3 | 2005 | 268 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1344 | 0.110 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2013 | 5 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 328 | 0.110 |
Why?
|
| Autoantigens | 1 | 2014 | 118 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2016 | 235 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 1351 | 0.110 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2013 | 67 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2023 | 2203 | 0.110 |
Why?
|
| Clinical Trials as Topic | 4 | 2008 | 1161 | 0.110 |
Why?
|
| Serologic Tests | 1 | 2014 | 130 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 36 | 0.110 |
Why?
|
| Pituitary Neoplasms | 1 | 1994 | 85 | 0.110 |
Why?
|
| New York | 1 | 2013 | 73 | 0.110 |
Why?
|
| Optic Neuritis | 1 | 2014 | 35 | 0.110 |
Why?
|
| Ventriculoperitoneal Shunt | 2 | 2009 | 58 | 0.100 |
Why?
|
| Sigmoid Diseases | 1 | 1993 | 7 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 143 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 357 | 0.100 |
Why?
|
| Topotecan | 1 | 2013 | 50 | 0.100 |
Why?
|
| Sepsis | 1 | 2018 | 519 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2013 | 105 | 0.100 |
Why?
|
| Nerve Compression Syndromes | 1 | 1993 | 18 | 0.100 |
Why?
|
| Laminectomy | 1 | 1993 | 24 | 0.100 |
Why?
|
| Lung | 1 | 2021 | 1577 | 0.100 |
Why?
|
| Spinal Nerve Roots | 1 | 1993 | 20 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2013 | 8 | 0.100 |
Why?
|
| RNA, Untranslated | 1 | 2014 | 120 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2016 | 505 | 0.100 |
Why?
|
| Blood Proteins | 2 | 2024 | 138 | 0.100 |
Why?
|
| Cell Differentiation | 4 | 2025 | 2043 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1993 | 71 | 0.100 |
Why?
|
| Diverticulum | 1 | 1993 | 30 | 0.100 |
Why?
|
| Spinal Cord Compression | 1 | 1993 | 34 | 0.100 |
Why?
|
| Intestinal Perforation | 1 | 1993 | 56 | 0.100 |
Why?
|
| Facial Paralysis | 1 | 1993 | 34 | 0.100 |
Why?
|
| Memory | 1 | 2016 | 358 | 0.100 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 1205 | 0.100 |
Why?
|
| Intracranial Aneurysm | 1 | 1993 | 84 | 0.100 |
Why?
|
| Epitopes | 1 | 2014 | 444 | 0.100 |
Why?
|
| Cerebral Ventricles | 2 | 2012 | 84 | 0.100 |
Why?
|
| Medical Records | 1 | 2013 | 194 | 0.100 |
Why?
|
| Functional Laterality | 2 | 2011 | 196 | 0.100 |
Why?
|
| Aspartic Acid | 1 | 2013 | 86 | 0.100 |
Why?
|
| Blood Platelets | 1 | 2015 | 342 | 0.100 |
Why?
|
| Neurilemmoma | 1 | 1993 | 48 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 202 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2013 | 187 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2025 | 8635 | 0.100 |
Why?
|
| Neurologic Examination | 2 | 2007 | 204 | 0.090 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 37 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 652 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 2 | 2004 | 134 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 645 | 0.090 |
Why?
|
| Administration, Oral | 4 | 2025 | 725 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 572 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 464 | 0.090 |
Why?
|
| Organ Size | 3 | 2017 | 467 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1044 | 0.090 |
Why?
|
| Blood Platelet Disorders | 1 | 2011 | 14 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 475 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 295 | 0.090 |
Why?
|
| Blood Coagulation Tests | 1 | 2011 | 62 | 0.090 |
Why?
|
| Magnetoencephalography | 1 | 2011 | 35 | 0.090 |
Why?
|
| Brain Diseases | 2 | 2014 | 310 | 0.090 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2011 | 18 | 0.090 |
Why?
|
| Platelet Aggregation | 1 | 2011 | 125 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 106 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1993 | 344 | 0.090 |
Why?
|
| Suction | 1 | 2011 | 56 | 0.090 |
Why?
|
| RNA, Messenger | 5 | 2017 | 2915 | 0.080 |
Why?
|
| Haplotypes | 2 | 2022 | 559 | 0.080 |
Why?
|
| Combined Modality Therapy | 5 | 2010 | 1312 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2011 | 261 | 0.080 |
Why?
|
| Animals, Newborn | 1 | 2013 | 1041 | 0.080 |
Why?
|
| Cerebrospinal Fluid | 2 | 2002 | 99 | 0.080 |
Why?
|
| Internet | 1 | 2013 | 403 | 0.080 |
Why?
|
| Blood Coagulation Disorders | 1 | 2011 | 110 | 0.080 |
Why?
|
| Visual Acuity | 1 | 2014 | 712 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 4006 | 0.080 |
Why?
|
| Interleukin-17 | 2 | 2024 | 130 | 0.080 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3758 | 0.080 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2009 | 17 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2010 | 221 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2009 | 373 | 0.080 |
Why?
|
| Paresis | 1 | 2009 | 33 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2025 | 2315 | 0.080 |
Why?
|
| Bacteria | 2 | 2024 | 537 | 0.080 |
Why?
|
| Cranial Nerve Diseases | 1 | 2009 | 27 | 0.080 |
Why?
|
| Health Status | 2 | 2009 | 413 | 0.080 |
Why?
|
| Risk Factors | 8 | 2021 | 11184 | 0.080 |
Why?
|
| Biopsy | 4 | 2015 | 1301 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 1051 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 867 | 0.080 |
Why?
|
| Antigens, Surface | 3 | 1985 | 120 | 0.070 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2009 | 51 | 0.070 |
Why?
|
| Health Surveys | 1 | 2009 | 262 | 0.070 |
Why?
|
| Cognition | 2 | 2014 | 819 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 7232 | 0.070 |
Why?
|
| Intelligence | 2 | 2016 | 107 | 0.070 |
Why?
|
| Medulla Oblongata | 1 | 2008 | 23 | 0.070 |
Why?
|
| Wakefulness | 1 | 2009 | 104 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 320 | 0.070 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 238 | 0.070 |
Why?
|
| HLA-DRB1 Chains | 2 | 2022 | 45 | 0.070 |
Why?
|
| Software | 1 | 2013 | 735 | 0.070 |
Why?
|
| Carcinoma | 1 | 2011 | 321 | 0.070 |
Why?
|
| Syndrome | 2 | 2022 | 1176 | 0.070 |
Why?
|
| Peptides | 2 | 2012 | 864 | 0.070 |
Why?
|
| Lactosylceramides | 2 | 2020 | 7 | 0.070 |
Why?
|
| Age Factors | 3 | 2015 | 2997 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 454 | 0.070 |
Why?
|
| Lumbosacral Region | 1 | 2007 | 25 | 0.070 |
Why?
|
| Equipment Failure | 3 | 2010 | 133 | 0.070 |
Why?
|
| Autistic Disorder | 1 | 2011 | 376 | 0.070 |
Why?
|
| Pregnancy | 3 | 2025 | 7599 | 0.070 |
Why?
|
| Hospitalization | 1 | 2016 | 1908 | 0.070 |
Why?
|
| Social Support | 1 | 2009 | 389 | 0.070 |
Why?
|
| Emotions | 2 | 2024 | 365 | 0.070 |
Why?
|
| Paraplegia | 1 | 2007 | 89 | 0.070 |
Why?
|
| Neoplasm, Residual | 2 | 1999 | 134 | 0.070 |
Why?
|
| Acute Disease | 2 | 2007 | 1190 | 0.070 |
Why?
|
| Contrast Media | 4 | 2016 | 517 | 0.070 |
Why?
|
| Surgical Flaps | 1 | 2008 | 197 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2013 | 1722 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2014 | 972 | 0.060 |
Why?
|
| Incidence | 3 | 2024 | 3421 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 2005 | 1183 | 0.060 |
Why?
|
| Proteins | 2 | 2003 | 1100 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 1985 | 695 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2022 | 780 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2009 | 484 | 0.060 |
Why?
|
| Reference Values | 1 | 2007 | 738 | 0.060 |
Why?
|
| Zinc Finger Protein GLI1 | 2 | 2002 | 37 | 0.060 |
Why?
|
| Iron | 1 | 2009 | 305 | 0.060 |
Why?
|
| Microarray Analysis | 2 | 2018 | 239 | 0.060 |
Why?
|
| Neural Pathways | 1 | 2007 | 283 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 399 | 0.060 |
Why?
|
| Algorithms | 3 | 2023 | 1738 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2020 | 810 | 0.060 |
Why?
|
| Smad2 Protein | 1 | 2025 | 53 | 0.060 |
Why?
|
| Antigens, Ly | 1 | 1984 | 35 | 0.060 |
Why?
|
| Mitochondria, Liver | 1 | 1985 | 36 | 0.060 |
Why?
|
| Interleukin-23 | 1 | 2024 | 15 | 0.060 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 1985 | 45 | 0.060 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2024 | 53 | 0.060 |
Why?
|
| Neoplasms | 1 | 2000 | 3034 | 0.060 |
Why?
|
| Acoustic Stimulation | 1 | 2024 | 86 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 1984 | 125 | 0.060 |
Why?
|
| Belgium | 2 | 2014 | 44 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2793 | 0.060 |
Why?
|
| Pinealoma | 1 | 2024 | 23 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2025 | 186 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 149 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 1144 | 0.050 |
Why?
|
| Gene Expression | 2 | 2021 | 1622 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2017 | 440 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2024 | 93 | 0.050 |
Why?
|
| Equipment Design | 2 | 2016 | 609 | 0.050 |
Why?
|
| Parents | 1 | 2011 | 1072 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 399 | 0.050 |
Why?
|
| Neuronavigation | 2 | 2015 | 10 | 0.050 |
Why?
|
| Smoking | 1 | 2009 | 1135 | 0.050 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2003 | 50 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 1880 | 0.050 |
Why?
|
| Syncope | 1 | 2023 | 54 | 0.050 |
Why?
|
| Corpus Callosum | 1 | 2023 | 104 | 0.050 |
Why?
|
| Peptide Fragments | 2 | 2020 | 832 | 0.050 |
Why?
|
| Public Opinion | 1 | 2023 | 62 | 0.050 |
Why?
|
| Reoviridae Infections | 1 | 1983 | 8 | 0.050 |
Why?
|
| Antigens | 2 | 2008 | 153 | 0.050 |
Why?
|
| Alleles | 2 | 2022 | 1724 | 0.050 |
Why?
|
| Clostridiales | 1 | 2022 | 9 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1983 | 81 | 0.050 |
Why?
|
| Dacarbazine | 1 | 2003 | 99 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 136 | 0.050 |
Why?
|
| Receptors, GABA | 1 | 2022 | 19 | 0.050 |
Why?
|
| Cell Movement | 2 | 2003 | 920 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2004 | 345 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 104 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 42 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2022 | 39 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 1983 | 111 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 1108 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2023 | 154 | 0.050 |
Why?
|
| Retroviridae | 1 | 2002 | 198 | 0.050 |
Why?
|
| Lymphocytes | 2 | 1987 | 433 | 0.050 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2001 | 7 | 0.050 |
Why?
|
| Demography | 2 | 2013 | 247 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2022 | 333 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2002 | 400 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 1983 | 89 | 0.050 |
Why?
|
| Registries | 2 | 2021 | 1586 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2022 | 32 | 0.050 |
Why?
|
| Cerebral Aqueduct | 1 | 2001 | 11 | 0.050 |
Why?
|
| Knowledge | 1 | 2022 | 51 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 108 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3677 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 2 | 2019 | 231 | 0.050 |
Why?
|
| alpha-Synuclein | 1 | 2022 | 134 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 56 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2003 | 360 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2021 | 26 | 0.040 |
Why?
|
| Canada | 1 | 2022 | 346 | 0.040 |
Why?
|
| Discoidin Domain Receptors | 1 | 2000 | 3 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2002 | 156 | 0.040 |
Why?
|
| Logistic Models | 2 | 2021 | 1908 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2001 | 142 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2025 | 1713 | 0.040 |
Why?
|
| British Columbia | 1 | 2020 | 11 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2001 | 75 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2022 | 254 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2005 | 742 | 0.040 |
Why?
|
| Risk | 1 | 2022 | 833 | 0.040 |
Why?
|
| Hydroxybutyrates | 1 | 2020 | 45 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 123 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 432 | 0.040 |
Why?
|
| Models, Biological | 1 | 2006 | 1538 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 1982 | 0.040 |
Why?
|
| Research | 1 | 2022 | 272 | 0.040 |
Why?
|
| Gestational Age | 1 | 2024 | 1230 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1387 | 0.040 |
Why?
|
| Protein Binding | 1 | 2024 | 1860 | 0.040 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2000 | 8 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 81 | 0.040 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2000 | 26 | 0.040 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2000 | 26 | 0.040 |
Why?
|
| Mice, Inbred DBA | 1 | 2019 | 56 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 399 | 0.040 |
Why?
|
| Selection Bias | 1 | 1999 | 22 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 2949 | 0.040 |
Why?
|
| Biological Assay | 1 | 2020 | 112 | 0.040 |
Why?
|
| Nitriles | 1 | 2020 | 155 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 219 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 134 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 45 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2025 | 749 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2019 | 53 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 237 | 0.040 |
Why?
|
| Birth Injuries | 1 | 1999 | 22 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2019 | 70 | 0.040 |
Why?
|
| Sirolimus | 2 | 2013 | 239 | 0.040 |
Why?
|
| Aminosalicylic Acid | 1 | 2018 | 2 | 0.040 |
Why?
|
| Panama | 1 | 2018 | 14 | 0.040 |
Why?
|
| Maxilla | 1 | 2019 | 39 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 51 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 78 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 2137 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 617 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2018 | 65 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1999 | 118 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 144 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 827 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 282 | 0.040 |
Why?
|
| Kinetics | 2 | 2014 | 1353 | 0.040 |
Why?
|
| Head | 1 | 2019 | 113 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 41 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2016 | 2562 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 1595 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2018 | 39 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2018 | 41 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2003 | 874 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 169 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 385 | 0.040 |
Why?
|
| Salvage Therapy | 2 | 2010 | 202 | 0.030 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2017 | 25 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 728 | 0.030 |
Why?
|
| Arrestin | 1 | 1997 | 3 | 0.030 |
Why?
|
| Intracranial Hypertension | 1 | 1999 | 134 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1735 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 1999 | 138 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 310 | 0.030 |
Why?
|
| Cervical Cord | 1 | 2017 | 10 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2017 | 21 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 1721 | 0.030 |
Why?
|
| Growth Disorders | 1 | 1999 | 224 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 567 | 0.030 |
Why?
|
| Uveitis | 1 | 1997 | 38 | 0.030 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1996 | 18 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2017 | 31 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 119 | 0.030 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2016 | 24 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1019 | 0.030 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2017 | 134 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2017 | 153 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 306 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 2 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Ganglioglioma | 1 | 1996 | 22 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 132 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2016 | 19 | 0.030 |
Why?
|
| Pheochromocytoma | 1 | 1996 | 40 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2016 | 120 | 0.030 |
Why?
|
| Granzymes | 1 | 2016 | 48 | 0.030 |
Why?
|
| Visual Cortex | 1 | 2018 | 131 | 0.030 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 1996 | 56 | 0.030 |
Why?
|
| Thiazoles | 1 | 2016 | 104 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 87 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 74 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2015 | 3752 | 0.030 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 1995 | 18 | 0.030 |
Why?
|
| Spinal Dysraphism | 1 | 2019 | 274 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 49 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2008 | 485 | 0.030 |
Why?
|
| Platelet Activating Factor | 1 | 2015 | 27 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2019 | 539 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1996 | 82 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2015 | 61 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 2015 | 23 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 723 | 0.030 |
Why?
|
| Radiography | 2 | 2014 | 826 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 437 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 363 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 277 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2016 | 1664 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3714 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 143 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2018 | 419 | 0.030 |
Why?
|
| Pituitary Irradiation | 1 | 1994 | 1 | 0.030 |
Why?
|
| Hypophysectomy | 1 | 1994 | 21 | 0.030 |
Why?
|
| Dandy-Walker Syndrome | 1 | 1995 | 11 | 0.030 |
Why?
|
| Spinal Cord Diseases | 1 | 2015 | 36 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 382 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 912 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 246 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 396 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 489 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 68 | 0.030 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2014 | 13 | 0.030 |
Why?
|
| Gait | 1 | 1995 | 141 | 0.030 |
Why?
|
| Natalizumab | 1 | 2014 | 3 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2014 | 27 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 401 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 1994 | 89 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2014 | 49 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 799 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1994 | 168 | 0.030 |
Why?
|
| Cell Shape | 1 | 2014 | 70 | 0.030 |
Why?
|
| Serotonin | 1 | 2015 | 226 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 699 | 0.030 |
Why?
|
| Renin | 1 | 1994 | 88 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 134 | 0.030 |
Why?
|
| Poland | 1 | 2014 | 51 | 0.030 |
Why?
|
| RNA Isoforms | 1 | 2013 | 6 | 0.030 |
Why?
|
| Ranvier's Nodes | 1 | 2014 | 74 | 0.030 |
Why?
|
| Phorbol Esters | 1 | 2013 | 23 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 54 | 0.030 |
Why?
|
| Occult Blood | 1 | 1993 | 32 | 0.030 |
Why?
|
| Nerve Degeneration | 1 | 2014 | 131 | 0.030 |
Why?
|
| Spinal Stenosis | 1 | 1993 | 10 | 0.030 |
Why?
|
| Abdomen, Acute | 1 | 1993 | 14 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3978 | 0.030 |
Why?
|
| Inositol | 1 | 2013 | 14 | 0.030 |
Why?
|
| Retina | 1 | 1997 | 501 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 1993 | 106 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 370 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 358 | 0.030 |
Why?
|
| Duodenal Diseases | 1 | 1993 | 34 | 0.030 |
Why?
|
| Creatine | 1 | 2013 | 40 | 0.030 |
Why?
|
| Sample Size | 1 | 2013 | 88 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1678 | 0.030 |
Why?
|
| Peritonitis | 1 | 1993 | 80 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1993 | 100 | 0.020 |
Why?
|
| Choline | 1 | 2013 | 56 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 720 | 0.020 |
Why?
|
| Diplopia | 1 | 1993 | 38 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 709 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 611 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 676 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2012 | 122 | 0.020 |
Why?
|
| Vitamin D | 1 | 2014 | 180 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1193 | 0.020 |
Why?
|
| Family | 1 | 2015 | 597 | 0.020 |
Why?
|
| Glutamine | 1 | 2013 | 222 | 0.020 |
Why?
|
| Videotape Recording | 2 | 2002 | 58 | 0.020 |
Why?
|
| Treatment Failure | 1 | 1993 | 365 | 0.020 |
Why?
|
| Molecular Sequence Annotation | 1 | 2012 | 163 | 0.020 |
Why?
|
| Parietal Lobe | 2 | 2002 | 49 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 1163 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 400 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2014 | 415 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 3876 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3799 | 0.020 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1991 | 6 | 0.020 |
Why?
|
| Arginine | 1 | 2013 | 351 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1991 | 15 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2011 | 93 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 151 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 824 | 0.020 |
Why?
|
| Walking | 1 | 2013 | 233 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2010 | 71 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 701 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 1993 | 273 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1993 | 190 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1945 | 0.020 |
Why?
|
| Depression | 1 | 2019 | 1365 | 0.020 |
Why?
|
| Camptothecin | 1 | 2010 | 79 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2010 | 79 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1969 | 40 | 0.020 |
Why?
|
| Jews | 1 | 1969 | 35 | 0.020 |
Why?
|
| Brain Infarction | 1 | 2009 | 31 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 734 | 0.020 |
Why?
|
| Cerebral Palsy | 1 | 2010 | 86 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 1994 | 603 | 0.020 |
Why?
|
| Subacute Sclerosing Panencephalitis | 1 | 1988 | 3 | 0.020 |
Why?
|
| DNA Probes | 2 | 2003 | 126 | 0.020 |
Why?
|
| Electrodes | 2 | 2007 | 91 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 1167 | 0.020 |
Why?
|
| Debridement | 1 | 2008 | 92 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 1988 | 26 | 0.020 |
Why?
|
| Meningoencephalitis | 1 | 1988 | 22 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 333 | 0.020 |
Why?
|
| Sclerosis | 1 | 2008 | 38 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 406 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 317 | 0.020 |
Why?
|
| Giant Cells | 1 | 2008 | 36 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2007 | 49 | 0.020 |
Why?
|
| Vimentin | 1 | 2008 | 70 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2008 | 94 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2008 | 367 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 606 | 0.020 |
Why?
|
| Rett Syndrome | 1 | 2010 | 294 | 0.020 |
Why?
|
| Cortical Synchronization | 1 | 2007 | 12 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2008 | 458 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1985 | 43 | 0.020 |
Why?
|
| Prevalence | 1 | 1993 | 2683 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 239 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 1985 | 5 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 2005 | 34 | 0.010 |
Why?
|
| Child Behavior Disorders | 1 | 2005 | 70 | 0.010 |
Why?
|
| Diethyl Pyrocarbonate | 1 | 1985 | 1 | 0.010 |
Why?
|
| Mesna | 1 | 2004 | 7 | 0.010 |
Why?
|
| Hypertension | 1 | 1994 | 1407 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2010 | 717 | 0.010 |
Why?
|
| Methicillin Resistance | 1 | 2005 | 118 | 0.010 |
Why?
|
| Microdissection | 1 | 2004 | 14 | 0.010 |
Why?
|
| Ribosomal Protein S6 | 1 | 2004 | 14 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 21 | 0.010 |
Why?
|
| Leucovorin | 1 | 2004 | 54 | 0.010 |
Why?
|
| Histidine | 1 | 1985 | 75 | 0.010 |
Why?
|
| Antilymphocyte Serum | 1 | 1984 | 42 | 0.010 |
Why?
|
| Meningitis | 1 | 2005 | 101 | 0.010 |
Why?
|
| Disulfiram | 1 | 1985 | 33 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1984 | 98 | 0.010 |
Why?
|
| Horses | 1 | 1985 | 102 | 0.010 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2004 | 37 | 0.010 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2004 | 45 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2008 | 790 | 0.010 |
Why?
|
| Etoposide | 1 | 2004 | 120 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 286 | 0.010 |
Why?
|
| Cell Count | 1 | 2004 | 241 | 0.010 |
Why?
|
| Cysteine | 1 | 1985 | 143 | 0.010 |
Why?
|
| Vincristine | 1 | 2004 | 196 | 0.010 |
Why?
|
| Spleen | 1 | 1984 | 289 | 0.010 |
Why?
|
| Mammalian orthoreovirus 3 | 1 | 1983 | 7 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 287 | 0.010 |
Why?
|
| Research Design | 1 | 1987 | 756 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 2771 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1983 | 251 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1984 | 397 | 0.010 |
Why?
|
| Methotrexate | 1 | 2004 | 355 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 472 | 0.010 |
Why?
|
| Tectum Mesencephali | 1 | 2001 | 3 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1984 | 1087 | 0.010 |
Why?
|
| Veratrum Alkaloids | 1 | 2001 | 13 | 0.010 |
Why?
|
| Random Allocation | 1 | 1983 | 446 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2001 | 53 | 0.010 |
Why?
|
| Vasopressins | 1 | 2001 | 45 | 0.010 |
Why?
|
| Point Mutation | 1 | 2003 | 362 | 0.010 |
Why?
|
| Binding Sites | 1 | 1985 | 1386 | 0.010 |
Why?
|
| Electrolytes | 1 | 2001 | 55 | 0.010 |
Why?
|
| Language Disorders | 1 | 2001 | 26 | 0.010 |
Why?
|
| Aldosterone | 1 | 2001 | 68 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2001 | 99 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 111 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 1138 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 2001 | 239 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2001 | 148 | 0.010 |
Why?
|
| Sodium | 1 | 2001 | 308 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2005 | 573 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 773 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 571 | 0.010 |
Why?
|
| DNA | 1 | 1985 | 1684 | 0.010 |
Why?
|
| Resuscitation | 1 | 2001 | 268 | 0.010 |
Why?
|
| Life Tables | 1 | 1997 | 28 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1997 | 105 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2002 | 857 | 0.010 |
Why?
|
| Safety | 1 | 1997 | 217 | 0.010 |
Why?
|
| Cattle | 1 | 1997 | 589 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 2177 | 0.010 |
Why?
|
| Cranial Nerve Injuries | 1 | 1995 | 5 | 0.010 |
Why?
|
| Anorexia Nervosa | 1 | 1974 | 30 | 0.010 |
Why?
|
| Defense Mechanisms | 1 | 1994 | 12 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1974 | 142 | 0.010 |
Why?
|
| Foreign-Body Migration | 1 | 1995 | 61 | 0.010 |
Why?
|
| Anger | 1 | 1994 | 30 | 0.010 |
Why?
|
| Cysts | 1 | 1995 | 104 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1994 | 176 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 222 | 0.010 |
Why?
|
| Aminopyrine | 1 | 1969 | 7 | 0.010 |
Why?
|
| Chloramphenicol | 1 | 1969 | 26 | 0.010 |
Why?
|
| Israel | 1 | 1969 | 48 | 0.010 |
Why?
|
| Dreams | 1 | 1969 | 23 | 0.000 |
Why?
|
| Anemia, Aplastic | 1 | 1969 | 62 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1969 | 290 | 0.000 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1969 | 91 | 0.000 |
Why?
|
| Psychotic Disorders | 1 | 1969 | 150 | 0.000 |
Why?
|
| Anxiety | 1 | 1994 | 1005 | 0.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1987 | 77 | 0.000 |
Why?
|
| Base Sequence | 1 | 1991 | 3180 | 0.000 |
Why?
|
| HIV Infections | 1 | 1996 | 2073 | 0.000 |
Why?
|
| Fluorescence | 1 | 1980 | 103 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1980 | 252 | 0.000 |
Why?
|
| Nervous System Diseases | 1 | 1980 | 411 | 0.000 |
Why?
|
| Amenorrhea | 1 | 1974 | 21 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1974 | 111 | 0.000 |
Why?
|
| Sleep Stages | 1 | 1974 | 33 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1974 | 69 | 0.000 |
Why?
|
| Menarche | 1 | 1974 | 37 | 0.000 |
Why?
|
| Puberty | 1 | 1974 | 104 | 0.000 |
Why?
|
| Body Weight | 1 | 1974 | 1041 | 0.000 |
Why?
|
| Interview, Psychological | 1 | 1969 | 107 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1969 | 890 | 0.000 |
Why?
|